Eloralintide
A selective amylin receptor agonist from Eli Lilly that has moved into Phase 3 obesity trials.
Also referenced as: LY3841136
Also appears in: Hormone
This compound has a genuine development or study trail, but it is not an approved routine drug.
Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.
LY3841136
No FDA label signal · 16 trials · 5 PubMed results
What eloralintide is
Eloralintide is Eli Lilly’s investigational selective amylin receptor agonist for obesity and overweight.
Why it matters
It gives the library a major amylin-only obesity candidate, which helps separate it from dual-pathway agents like amycretin or petrelintide combination narratives. The fact that it has already advanced into Phase 3 makes it much more than a speculative name.
Regulatory context
Eloralintide is not FDA approved. It sits firmly in the late-stage investigational category.
Practical reading note
This is one of the better examples of why not every important obesity peptide is another GLP-1 story. Amylin-focused drugs are now a real lane of their own.